ALX Oncology is laying off 30% of its staff, mainly in preclinical research, to redirect money toward clinical trials, ...

ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 ...

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article ...

The Army Leader Exchange’s third annual March Masters professional development content creator competition will run March 16 ...

Small-Cap Firms Dominate Market Rally. In this article, we are going to take a look at where ALX Oncology Holdings Inc.

ALX Oncology is cutting about 30% of its workforce and realigning its focus. The clinical-stage biotechnology company named Harish Shantharam as chief financial officer and Alan Sandler as chief ...

ALX Oncology Holdings Inc.’s ALXO share price has dipped by 19.08%, which has investors questioning if this is right time to ...

ASX:ALX Earnings and Revenue History March 11th 2025 The Impact Of Unusual Items On Profit. To properly understand Atlas ...

Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in ...

Shares of ALX Oncology (NASDAQ:ALXO) climbed on Thursday after Jefferies upgraded the cancer drug developer to Buy from Hold, arguing that its stock, following the recent selloff, has the potential to ...

ALX Oncology (ALXO) will highlight progress across its clinical pipeline, including continued advancement of investigational CD47-blocker ...